Dossier assessment

Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-86
Last updated

Report documents

  1. Extract of dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 633 kB, EN, not accessible
  2. Dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 2 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-86

Dossier assessment

Indication:

Adult patients with unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least 2 additional systemic therapies in the advanced setting

Result of dossier assessment:

Hint of minor added benefit

Press releases

Early benefit assessment: Informative RCTs are also feasible in later lines of oncological treatment

Two randomized controlled trials in third- and fourth-line treatments for colorectal and breast cancer each show an added benefit for the drugs assessed.

Additional information

Federal Joint Committee (G-BA)

2024-02-15 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-86
Commission
Commission awarded on 15.08.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://dx.doi.org/10.60584/A23-86

Connected Projects

  1. Dossier assessment

    Sacituzumab (breast cancer) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A21-154
    Last updated

    Status: Commission completed

  2. Addendum

    Sacituzumab govitecan (breast cancer) – Addendum to Project A23-86

    Project no.
    A24-07
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Sacituzumab govitecan (breast cancer) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A26-95
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form